Skip to main content
SpringerLink
Log in

Stem Cell Therapy and Regenerative Medicine for ARDS: Can Stem Cell Therapy and Regenerative Medicine Contribute to the Protection or Recovery of the Injured Lungs?

  • Chapter
  • First Online:
Acute Respiratory Distress Syndrome

  • 1364 Accesses

Abstract

Acute respiratory distress syndrome (ARDS) is a life-threatening severe acute respiratory failure syndrome characterized by rapid onset of widespread inflammation in the lungs and subsequent increased permeability of the pulmonary capillary endothelial and alveolar epithelial barriers, leading to severe progressive hypoxemia and frequent need for mechanical ventilation. Despite recent improvements in the clinical management of ARDS patients, such as the use of respiratory support and fluid input restriction, there are no established pharmacological therapies, and the mortality rate of ARDS is still high. The recent global pandemic of coronavirus disease 2019 (COVID-19), which is caused by SARS-CoV-2 and often results in ARDS, has encouraged the rapid establishment of novel therapies. Cell-based therapies, primarily using mesenchymal stem/stromal cells, have been extensively reported in animal models and clinical studies as a promising approach for the treatment of ARDS mainly induced by various kinds of respiratory infections, including influenza virus and SARS-CoV-2. In this chapter, the current knowledge and future direction of stem cell therapy for ARDS will be reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Matthay MA, Zemans RL, Zimmerman GA, Arabi YM, Beitler JR, Mercat A, et al. Acute respiratory distress syndrome. Nat Rev Dis Primers. 2019;5(1):18. https://doi.org/10.1038/s41572-019-0069-0.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Laffey JG, Matthay MA. Fifty years of research in ARDS. Cell-based therapy for acute respiratory distress syndrome. Biology and potential therapeutic value. Am J Respir Crit Care Med. 2017;196(3):266–73. https://doi.org/10.1164/rccm.201701-0107CP.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Johns Hopkins University and Medicine. COVID-19 map. Johns Hopkins Coronavirus Resource Centre; 2020. https://coronavirus.jhu.edu/map.html. Accessed 3 October.

  4. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324(8):782–93. https://doi.org/10.1001/jama.2020.12839.

    Article  CAS  PubMed  Google Scholar 

  5. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the new York City area. JAMA. 2020;323(20):2052–9. https://doi.org/10.1001/jama.2020.6775.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ. 2020;369:m1985. https://doi.org/10.1136/bmj.m1985.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020;323(16):1574–81. https://doi.org/10.1001/jama.2020.5394.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19—preliminary report. N Engl J Med. 2020; https://doi.org/10.1056/NEJMoa2021436.

  9. Group WHOREAfC-TW, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1330–41. https://doi.org/10.1001/jama.2020.17023.

    Article  CAS  Google Scholar 

  10. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19—final report. N Engl J Med. 2020; https://doi.org/10.1056/NEJMoa2007764.

  11. Consortium WHOST, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, et al. Repurposed antiviral drugs for Covid-19—interim WHO solidarity trial results. N Engl J Med. 2020; https://doi.org/10.1056/NEJMoa2023184.

  12. Xiao K, Hou F, Huang X, Li B, Qian ZR, Xie L. Mesenchymal stem cells: current clinical progress in ARDS and COVID-19. Stem Cell Res Ther. 2020;11(1):305. https://doi.org/10.1186/s13287-020-01804-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Canham MA, Campbell JDM, Mountford JC. The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019. J Transl Med. 2020;18(1):359. https://doi.org/10.1186/s12967-020-02532-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Basil MC, Katzen J, Engler AE, Guo M, Herriges MJ, Kathiriya JJ, et al. The cellular and physiological basis for lung repair and regeneration: past, present, and future. Cell Stem Cell. 2020;26(4):482–502. https://doi.org/10.1016/j.stem.2020.03.009.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Guo M, Du Y, Gokey JJ, Ray S, Bell SM, Adam M, et al. Single cell RNA analysis identifies cellular heterogeneity and adaptive responses of the lung at birth. Nat Commun. 2019;10(1):37. https://doi.org/10.1038/s41467-018-07770-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Vieira Braga FA, Kar G, Berg M, Carpaij OA, Polanski K, Simon LM, et al. A cellular census of human lungs identifies novel cell states in health and in asthma. Nat Med. 2019;25(7):1153–63. https://doi.org/10.1038/s41591-019-0468-5.

    Article  CAS  PubMed  Google Scholar 

  17. Barkauskas CE, Cronce MJ, Rackley CR, Bowie EJ, Keene DR, Stripp BR, et al. Type 2 alveolar cells are stem cells in adult lung. J Clin Invest. 2013;123(7):3025–36. https://doi.org/10.1172/JCI68782.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Giangreco A, Arwert EN, Rosewell IR, Snyder J, Watt FM, Stripp BR. Stem cells are dispensable for lung homeostasis but restore airways after injury. Proc Natl Acad Sci U S A. 2009;106(23):9286–91. https://doi.org/10.1073/pnas.0900668106.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Liu Q, Liu K, Cui G, Huang X, Yao S, Guo W, et al. Lung regeneration by multipotent stem cells residing at the bronchioalveolar-duct junction. Nat Genet. 2019;51(4):728–38. https://doi.org/10.1038/s41588-019-0346-6.

    Article  CAS  PubMed  Google Scholar 

  20. Salwig I, Spitznagel B, Vazquez-Armendariz AI, Khalooghi K, Guenther S, Herold S, et al. Bronchioalveolar stem cells are a main source for regeneration of distal lung epithelia in vivo. EMBO J. 2019;38(12) https://doi.org/10.15252/embj.2019102099.

  21. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997;276(5309):71–4. https://doi.org/10.1126/science.276.5309.71.

    Article  CAS  PubMed  Google Scholar 

  22. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–7. https://doi.org/10.1080/14653240600855905.

    Article  CAS  PubMed  Google Scholar 

  23. Qin H, Zhao A. Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics. Protein Cell. 2020;11(10):707–22. https://doi.org/10.1007/s13238-020-00738-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Yen BL, Yen ML, Wang LT, Liu KJ, Sytwu HK. Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: gleaning insights for possible use in COVID-19. Stem Cells Transl Med. 2020; https://doi.org/10.1002/sctm.20-0186.

  25. Asami T, Ishii M, Namkoong H, Yagi K, Tasaka S, Asakura T, et al. Anti-inflammatory roles of mesenchymal stromal cells during acute Streptococcus pneumoniae pulmonary infection in mice. Cytotherapy. 2018;20(3):302–13. https://doi.org/10.1016/j.jcyt.2018.01.003.

    Article  CAS  PubMed  Google Scholar 

  26. Matthay MA, Calfee CS, Zhuo H, Thompson BT, Wilson JG, Levitt JE, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med. 2019;7(2):154–62. https://doi.org/10.1016/S2213-2600(18)30418-1.

    Article  PubMed  Google Scholar 

  27. Chen J, Hu C, Chen L, Tang L, Zhu Y, Xu X, et al. Clinical study of mesenchymal stem cell treatment for acute respiratory distress syndrome induced by epidemic influenza a (H7N9) infection: a hint for COVID-19 treatment. Engineering (Beijing). 2020;6(10):1153–61. https://doi.org/10.1016/j.eng.2020.02.006.

    Article  CAS  Google Scholar 

  28. Zacharias WJ, Frank DB, Zepp JA, Morley MP, Alkhaleel FA, Kong J, et al. Regeneration of the lung alveolus by an evolutionarily conserved epithelial progenitor. Nature. 2018;555(7695):251–5. https://doi.org/10.1038/nature25786.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Rosen C, Shezen E, Aronovich A, Klionsky YZ, Yaakov Y, Assayag M, et al. Preconditioning allows engraftment of mouse and human embryonic lung cells, enabling lung repair in mice. Nat Med. 2015;21(8):869–79. https://doi.org/10.1038/nm.3889.

    Article  CAS  PubMed  Google Scholar 

  30. Nichane M, Javed A, Sivakamasundari V, Ganesan M, Ang LT, Kraus P, et al. Isolation and 3D expansion of multipotent Sox9(+) mouse lung progenitors. Nat Methods. 2017;14(12):1205–12. https://doi.org/10.1038/nmeth.4498.

    Article  CAS  PubMed  Google Scholar 

  31. Miller AJ, Hill DR, Nagy MS, Aoki Y, Dye BR, Chin AM, et al. In vitro induction and in vivo engraftment of lung bud tip progenitor cells derived from human pluripotent stem cells. Stem Cell Rep. 2018;10(1):101–19. https://doi.org/10.1016/j.stemcr.2017.11.012.

    Article  CAS  Google Scholar 

  32. Hillel-Karniel C, Rosen C, Milman-Krentsis I, Orgad R, Bachar-Lustig E, Shezen E, et al. Multi-lineage lung regeneration by stem cell transplantation across major genetic barriers. Cell Rep. 2020;30(3):807–19 e4. https://doi.org/10.1016/j.celrep.2019.12.058.

    Article  CAS  PubMed  Google Scholar 

  33. Weiner AI, Jackson SR, Zhao G, Quansah KK, Farshchian JN, Neupauer KM, et al. Mesenchyme-free expansion and transplantation of adult alveolar progenitor cells: steps toward cell-based regenerative therapies. NPJ Regen Med. 2019;4:17. https://doi.org/10.1038/s41536-019-0080-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan

    Makoto Ishii

Authors
  1. Makoto Ishii
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Makoto Ishii .

Editor information

Editors and Affiliations

  1. Department of Respiratory Medicine, Hirosaki University, Graduate School of Medicine, Hirosaki, Japan

    Sadatomo Tasaka

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ishii, M. (2022). Stem Cell Therapy and Regenerative Medicine for ARDS: Can Stem Cell Therapy and Regenerative Medicine Contribute to the Protection or Recovery of the Injured Lungs?. In: Tasaka, S. (eds) Acute Respiratory Distress Syndrome. Respiratory Disease Series: Diagnostic Tools and Disease Managements. Springer, Singapore. https://doi.org/10.1007/978-981-16-8371-8_12

Download citation

  • DOI: https://doi.org/10.1007/978-981-16-8371-8_12

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-16-8370-1

  • Online ISBN: 978-981-16-8371-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation